RxDoctor Payments Data

Trenity McKinney, MD

Ophthalmology · Venice, FLNPI 1629030655

Payments from drug & device makers

$2,701in general payments, 2019–2025

Across 89 payments — averaging $30.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$660
  • Bausch & Lomb Americas Inc.$344
  • Biotissue Holdings Inc.$307
  • Sun Pharmaceutical Industries Inc.$274
  • Notal Vision, Inc.$217
  • AbbVie$203
  • plus $695 from 17 others

What the payments were for

  • Speaking & faculty fees$2178%
  • Travel & lodging$2027%
  • Food & beverage$2,28284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,701 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$461,049
Medicare patients
1,210
Services billed
4,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine94$151,009
VyzultaLatanoprostene Bunod79$53,856
ProlensaBromfenac Sodium72$24,977
XiidraLifitegrast14$19,172
Cyclosporine25$15,989
BesivanceBesifloxacin Hcl69$15,111
MieboPerfluorohexyloctane/Pf13$9,812
LumiganBimatoprost15$9,418
SimbrinzaBrinzolamide/Brimonidine Tart14$4,735
Bromfenac Sodium25$4,445
Latanoprost326$4,165
Difluprednate54$3,755
Dorzolamide-TimololDorzolamide/Timolol/Pf25$3,454
Brimonidine Tartrate28$3,161
Timolol Maleate298$2,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$203$160,426109 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$344$82,841106 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$114$40,088141 claims
AlconSimbrinza$660$4,73514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Venice

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →